Moogene Medi Co., Ltd. (XKON:322970)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,100.00
+10.00 (0.48%)
At close: May 13, 2025, 3:30 PM KST
-12.32%
Market Cap 20.93B
Revenue n/a
Net Income n/a
Shares Out 10.02M
EPS n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 601
Average Volume 1,019
Open 2,140.00
Previous Close 2,090.00
Day's Range 2,050.00 - 2,140.00
52-Week Range 1,350.00 - 3,090.00
Beta -0.02
RSI 41.60
Earnings Date n/a

About Moogene Medi

Moogene Medi Co., Ltd. develops gene therapies based on its proprietary gene-editing platform technology. The company’s product portfolio comprises MG-001, which is in Phase I clinical trials to treat colon cancer; MG-002 that is in preclinical stage for use in the treatment of pancreatic cancer; and MG-003, which is in preclinical stage for use in the treatment of diabetes mellitus. Its research stage products include MG-004 for treating hair loss and MG-005 for use in the treatment of Crohn's disease. The company was founded in 2016 and is ba... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange Korea New Exchange
Ticker Symbol 322970
Full Company Profile

News

There is no news available yet.